Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
2.070
+0.005 (0.24%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Soligenix Revenue
In the year 2024, Soligenix had annual revenue of $119.37K, down -85.78%.
Revenue (ttm)
$119.37K
Revenue Growth
-85.78%
P/S Ratio
28.79
Revenue / Employee
$7,461
Employees
16
Market Cap
6.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 119.37K | -719.99K | -85.78% |
| Dec 31, 2023 | 839.36K | -109.55K | -11.55% |
| Dec 31, 2022 | 948.91K | 124.64K | 15.12% |
| Dec 31, 2021 | 824.27K | -1.54M | -65.07% |
| Dec 31, 2020 | 2.36M | -2.27M | -49.04% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
SNGX News
- 10 days ago - Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks - PRNewsWire
- 4 weeks ago - IBN Initiates Coverage of Soligenix Inc. - GlobeNewsWire
- 4 weeks ago - Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants - PRNewsWire
- 4 weeks ago - Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results - PRNewsWire
- 6 weeks ago - HyBryte™ Treatment Studies Presented at Two Medical Conferences in March - PRNewsWire
- 2 months ago - Soligenix to Present at BIO CEO & Investor Conference - PRNewsWire
- 3 months ago - Soligenix to Present at Upcoming Investor Conferences - PRNewsWire
- 3 months ago - HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma - PRNewsWire